These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 24207016)

  • 1. Evaluation of laboratory methods routinely used to detect the effect of aspirin against new reference methods.
    Kovács EG; Katona É; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Édes I; Muszbek L
    Thromb Res; 2014 May; 133(5):811-6. PubMed ID: 24207016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New direct and indirect methods for the detection of cyclooxygenase 1 acetylation by aspirin; the lack of aspirin resistance among healthy individuals.
    Kovács EG; Katona E; Bereczky Z; Homoródi N; Balogh L; Tóth E; Péterfy H; Kiss RG; Edes I; Muszbek L
    Thromb Res; 2013 Apr; 131(4):320-4. PubMed ID: 23422285
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study.
    Gurbel PA; Bliden KP; DiChiara J; Newcomer J; Weng W; Neerchal NK; Gesheff T; Chaganti SK; Etherington A; Tantry US
    Circulation; 2007 Jun; 115(25):3156-64. PubMed ID: 17562955
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased platelet sensitivity among individuals with aspirin resistance - platelet aggregation to submaximal concentration of arachidonic acid predicts response to antiplatelet therapy.
    Guthikonda S; Mangalpally K; Vaduganathan M; Patel R; Delao T; Bergeron AL; Dong JF; Lev EI; Kleiman NS
    Thromb Haemost; 2008 Jul; 100(1):83-9. PubMed ID: 18612542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Association of cyclooxygenase-1-dependent and -independent platelet function assays with adverse clinical outcomes in aspirin-treated patients presenting for cardiac catheterization.
    Frelinger AL; Li Y; Linden MD; Barnard MR; Fox ML; Christie DJ; Furman MI; Michelson AD
    Circulation; 2009 Dec; 120(25):2586-96. PubMed ID: 19996015
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.
    Greenberg HE; Gottesdiener K; Huntington M; Wong P; Larson P; Wildonger L; Gillen L; Dorval E; Waldman SA
    J Clin Pharmacol; 2000 Dec; 40(12 Pt 2):1509-15. PubMed ID: 11185674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences.
    Anzellotti P; Capone ML; Jeyam A; Tacconelli S; Bruno A; Tontodonati P; Di Francesco L; Grossi L; Renda G; Merciaro G; Di Gregorio P; Price TS; Garcia Rodriguez LA; Patrignani P
    Arthritis Rheum; 2011 Mar; 63(3):850-9. PubMed ID: 21360514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance".
    Santilli F; Rocca B; De Cristofaro R; Lattanzio S; Pietrangelo L; Habib A; Pettinella C; Recchiuti A; Ferrante E; Ciabattoni G; Davì G; Patrono C
    J Am Coll Cardiol; 2009 Feb; 53(8):667-77. PubMed ID: 19232899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects.
    Maenthaisong R; Tacconelli S; Sritara P; Del Boccio P; Di Francesco L; Sacchetta P; Archararit N; Aryurachai K; Patrignani P; Suthisisang C
    Int J Immunopathol Pharmacol; 2013; 26(2):403-17. PubMed ID: 23755755
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual cyclooxygenase-1 activity and epinephrine reduce the antiplatelet effect of aspirin in patients with acute myocardial infarction.
    Moscardó A; Santos MT; Fuset MP; Ruano M; Vallés J
    Thromb Haemost; 2011 Apr; 105(4):663-9. PubMed ID: 21301784
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A comparison of platelet function tests and thromboxane metabolites to evaluate aspirin response in healthy individuals and patients with coronary artery disease.
    Grove EL; Hvas AM; Johnsen HL; Hedegaard SS; Pedersen SB; Mortensen J; Kristensen SD
    Thromb Haemost; 2010 Jun; 103(6):1245-53. PubMed ID: 20352155
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients.
    Lepäntalo A; Mikkelsson J; Reséndiz JC; Viiri L; Backman JT; Kankuri E; Karhunen PJ; Lassila R
    Thromb Haemost; 2006 Feb; 95(2):253-9. PubMed ID: 16493486
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interactions of gallic acid, resveratrol, quercetin and aspirin at the platelet cyclooxygenase-1 level. Functional and modelling studies.
    Crescente M; Jessen G; Momi S; Höltje HD; Gresele P; Cerletti C; de Gaetano G
    Thromb Haemost; 2009 Aug; 102(2):336-46. PubMed ID: 19652885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reticulated platelets and uninhibited COX-1 and COX-2 decrease the antiplatelet effects of aspirin.
    Guthikonda S; Lev EI; Patel R; DeLao T; Bergeron AL; Dong JF; Kleiman NS
    J Thromb Haemost; 2007 Mar; 5(3):490-6. PubMed ID: 17319904
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease.
    Lordkipanidzé M; Pharand C; Schampaert E; Turgeon J; Palisaitis DA; Diodati JG
    Eur Heart J; 2007 Jul; 28(14):1702-8. PubMed ID: 17569678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lack of biological relevance of platelet cyclooxygenase-2 dependent thromboxane A2 production.
    Riondino S; Trifirò E; Principessa L; Mascioletti S; Di Renzo L; Gaudio C; Biasucci LM; Crea F; Pulcinelli FM
    Thromb Res; 2008; 122(3):359-65. PubMed ID: 18295304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the antiplatelet effects of low to medium dose aspirin in the early and late phases after ischaemic stroke and TIA.
    McCabe DJ; Harrison P; Mackie IJ; Sidhu PS; Lawrie AS; Purdy G; Machin SJ; Brown MM
    Platelets; 2005 Aug; 16(5):269-80. PubMed ID: 16011977
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of aspirin and clopidogrel in healthy men measured by platelet aggregation and PFA-100.
    Madsen EH; Schmidt EB; Maurer-Spurej E; Kristensen SR
    Platelets; 2008 Aug; 19(5):335-41. PubMed ID: 18791939
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dose- and time-dependent antiplatelet effects of aspirin.
    Perneby C; Wallén NH; Rooney C; Fitzgerald D; Hjemdahl P
    Thromb Haemost; 2006 Apr; 95(4):652-8. PubMed ID: 16601836
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Arachidonic acid-stimulated platelet tests: Identification of patients less sensitive to aspirin treatment.
    Temperilli F; Rina A; Massimi I; Montemari AL; Guarino ML; Zicari A; Pulcinelli FM
    Platelets; 2015; 26(8):783-7. PubMed ID: 25734355
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.